Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

169
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
169
Regulation of Water Output01:26

Regulation of Water Output

267
The human body predominantly expels water through the urinary system. On average, an individual generates around 1.5 liters of urine each day. This amount can fluctuate based on how well a person is hydrated, but a critical minimum quantity of urine must be produced to ensure the body's proper functioning. Daily, the kidneys remove 600 to 1200 milliosmoles of dissolved substances, effectively excreting excess minerals and water-soluble toxins such as creatinine, urea, and uric acid from the...
267
The Micturition Reflex01:26

The Micturition Reflex

440
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
440
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

[Pharmacological treatment of overactive bladder: the potential of anticholinergic therapy].

Urologiia (Moscow, Russia : 1999)·2025
Same author

[The use of the combined drug Urolife-Next for recurrent lower urinary tract infections: clinical and microbiological aspects].

Urologiia (Moscow, Russia : 1999)·2024
Same journal

[Outcomes of Surgical Correction of the Urethra in the Management of Postcoital Cystitis: A Systematic Review and Meta-Analysis].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Use of Longidaza in chronic prostatitis: A systematic review and meta-analysis].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Epidemiology, risk factors, diagnosis, and microbiology of suppurative pyelonephritis: a systematic review and meta-analysis, part 1].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Endocrine and metabolic changes in prostate cancer patients after radical prostatectomy].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Risks of acute kidney injury with intravascular administration of an iodine-containing contrast agent in patients with acute pyelonephritis].

Urologiia (Moscow, Russia : 1999)·2025
See all related articles

Related Experiment Video

Updated: Jun 7, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.0K

[Bioregulatory therapy for overactive bladder].

V Kuzmin I1

  • 1FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia, Saint-Petersburg, Russia.

Urologiia (Moscow, Russia : 1999)
|November 20, 2024
PubMed
Summary
This summary is machine-generated.

A novel polypeptide drug, Vesusten, derived from animal bladder tissue, shows promise for treating overactive bladder. This review details its pathogenesis, clinical results, and therapeutic mechanisms.

Keywords:
Vesustenbioregulatory therapydetrusor overactivityoveractive bladderregulatory peptides

More Related Videos

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.2K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.2K

Related Experiment Videos

Last Updated: Jun 7, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.0K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.2K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.2K

Area of Science:

  • Urology
  • Pharmacology
  • Biochemistry

Background:

  • Overactive bladder (OAB) presents significant challenges in epidemiology and pathogenesis.
  • Current OAB treatments have limitations, necessitating novel therapeutic approaches.
  • Bioregulatory peptides offer a potential mechanism for physiological regulation.

Purpose of the Study:

  • To review the pathogenetic basis and clinical outcomes of Vesusten for OAB treatment.
  • To elucidate the mechanisms of peptide regulation in human physiological processes.
  • To discuss the preclinical and clinical data supporting Vesusten's efficacy.

Main Methods:

  • Review of epidemiological data and pathogenesis factors of OAB.
  • Analysis of current treatment modalities for overactive bladder.
  • Examination of preclinical and clinical study results for Vesusten.

Main Results:

  • Vesusten, a polypeptide-based drug from animal bladder tissue, is presented as an innovative treatment for OAB.
  • Detailed discussion of Vesusten's preclinical and clinical study outcomes.
  • Exploration of bioregulatory peptide mechanisms in therapeutic applications.

Conclusions:

  • Vesusten demonstrates potential as a novel therapeutic agent for overactive bladder.
  • Understanding peptide regulation is key to developing new treatments for OAB.
  • Further clinical evaluation of Vesusten is warranted based on preclinical and initial clinical findings.